Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
OBJECTIVE
To describe the biochemical and adverse effects of a convenient single 90 mg pamidronate dose in patients with acute spinal cord injury (SCI) and compare these effects with those observed in a previous similar study using a 30 mg/d x 3-day pamidronate dosing regimen.


METHODS
Retrospective cohort study.


METHODS
University-based rehabilitation center in New York City.


METHODS
A total of 32 patients with SCI were evaluated for biochemical response and adverse events associated with pamidronate therapy. All patients were screened at or near admission for acute rehabilitation, received calcium (1,000 mg daily) and calcitriol (0.25 micrg daily) therapy daily, and on day 4, received a single dose of pamidronate, 90 mg by intravenous infusion, over 4 hours. Serum calcium and phosphate levels were closely monitored, and 2 weeks after pamidronate, biochemical bone markers were re-evaluated.


RESULTS
Responses of biochemical markers of bone resorption (N-telopeptide and 24-hour urinary calcium excretion) to pamidronate 90 mg were consistent with an antiresorptive effect, although less than that observed with a 30 mg/d x 3-day pamidronate dosing regimen. The frequency of hypocalcemia was greater, and hypophosphatemia was less than the 30 mg/d x 3-day pamidronate dosing regimen. Fever was more frequent (78%) with the 90-mg single dose of pamidronate compared with the 30 mg/d x 3-day pamidronate dosing regimen (20%).


CONCLUSIONS
Single-dose pamidronate 90 mg is effective at reducing biochemical markers of bone hyperresorption in patients with acute SCI but is associated with a greater incidence of fever compared with a 30 mg/d x 3-day dosing regimen.
Mechanick
Jeffrey I
JI
Division of Endocrinology, Diabetes and Bone Disease, Mt Sinai School of Medicine, 1192 Park Avenue, New York, NY 10128, USA. jmechanik@aol.com
Liu
Kan
K
Nierman
David M
DM
Stein
Adam
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology; D015331:Cohort Studies; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D000077268:Pamidronate; D012189:Retrospective Studies; D013119:Spinal Cord Injuries / Q000378:metabolism*
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate